"Capecitabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.
| Descriptor ID |
D000069287
|
| MeSH Number(s) |
D03.383.742.680.245.500.425 D03.383.742.698.875.404.425 D13.570.230.329.313 D13.570.685.245.500.425
|
| Concept/Terms |
Capecitabine- Capecitabine
- N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
|
Below are MeSH descriptors whose meaning is more general than "Capecitabine".
Below are MeSH descriptors whose meaning is more specific than "Capecitabine".
This graph shows the total number of publications written about "Capecitabine" by people in this website by year, and whether "Capecitabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Capecitabine" by people in Profiles.
-
Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. Br J Cancer. 2017 May 09; 116(10):1264-1270.
-
Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):810-8.
-
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):317-26.
-
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011 Jan 15; 17(2):372-81.
-
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009 May; 115(1):115-21.
-
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):792-9.